Highlights

• Adheris Health (ASX:AHE) is repositioning its Business around higher-margin digital patient-engagement products.
• FY2026 Revenue declined materially, although the company achieved cashflow break-even in the final quarter.
• The THRiV platform is becoming a larger part of the company’s revenue mix and future pipeline.
• Cost reduction, pharmaceutical customer renewals and the ongoing US litigation remain key factors to monitor.

Adheris Health (ASX:AHE) — the pharmacy-network technology company Australian investors knew for years as MedAdvisor before its December 2025 rebrand — is in the middle of one of the more difficult turnarounds on the ASX healthcare boards. FY2026…